“I’m very excited to have joined such a forward thinking, innovative company as LUMEA, which is uniquely positioned to usher in the new age of digital pathology.” – Dr. Lash
LEHI, Utah (PRWEB)
October 15, 2020
Dr. Lash has extensive diagnostic experience in both academic and commercial environments, and has led the development of molecular diagnostics, clinical research, and biotechnology in several large organizations. Dr. Lash is taking on this role at LUMEA in addition to his current work as president of a medical consulting company in Texas and as Associate Clinical Professor of Pathology at UT-Southwestern Medical Center.
“We are pleased to have Dr. Lash join our company,” said John Wirthlin, Chief Executive Officer of LUMEA. “Dr. Lash is a nationally recognized pathologist who brings a wealth of medical and large-scale commercial laboratory experience to LUMEA. We are excited to work with Dr. Lash to establish our technology platform as the gold standard for digital pathology.”
Regarding his appointment, Dr. Lash said, “I’m very excited to have joined such a forward thinking, innovative company as LUMEA, which is uniquely positioned to usher in the new age of digital pathology by removing many of the obstacles that has stymied progress to date. LUMEA is driving cost saving measures while improving quality of both pre-analytic workflow and the diagnostic process itself.”
Previously, Dr. Lash was the CMO and EVP of Operations at Inform Diagnostics, formerly Caris Life Sciences, the largest independent anatomic pathology provider in the United States. He earned his medical degree from the University of Michigan and completed his residency in anatomic/clinical pathology at the Cleveland Clinic Foundation where he served as chief resident. He completed his fellowship in surgical pathology with subspecialty training in GI pathology. Dr. Lash has 84 research publications in major journals with over 1,300 citations and has written 6 book chapters. His research interests and experience will be an important driving factor in new product development and technology commercialization.
LUMEA is a leader in the commercialization of digital pathology technologies. Its proprietary system leverages biopsy handling technology, workflow improvements and the deployment of artificial intelligence in both pre-analytic and analytic phases of the diagnostic process. LUMEA’s technology results in measurably better quality and reduced time and cost throughout the diagnostic workflow. The company has commercialized the most advanced, fully integrated digital diagnostic platform on the market today, and its valued based business model is scaling nationally.
Share article on social media or email: